Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24603597 | 0.86 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL11796611 | 0.86 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL10636519 | 0.84 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL18431714 | 0.84 | HCAR2 (0.37) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL31065466 | 0.83 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3077876 | 0.81 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1131553 | 0.81 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3076436 | 0.79 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL15948445 | 0.79 | LMNA (0.42) | ALDH1A1TSHRALOX12LMNACYP2D6 | |
| SCHEMBL819913 | 0.78 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20180273517-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX INC (US) | 2018-09-27 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| EP-2215082-B1 | PHTHALAZINE AND PYRIDO[3,4-D]PYRIDAZINE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-7884114-B2 | N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide for treatment of allergic rhinitis | GLAXO GROUP LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-20100216799-A1 | PHTHALAZINE AND PYRIDO[3,4-D]PYRIDAZINE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-2215082-A1 | PHTHALAZINE AND PYRIDO Ý3,4-D¨PYRIDAZ INE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-08-11 | — | — | EP | disclosed |
| EP-2185542-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20090270355-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| WO-2009047336-A1 | PHTHALAZINE AND PYRIDO [3,4-D] PYRIDAZ INE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009021965-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216799-A1 | PHTHALAZINE AND PYRIDO[3,4-D]PYRIDAZINE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH1 | MGAM 4553/4885GAA 3089/4885SI 2677/4885 |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | MGAM 667/4885GAA 303/4885SI 34/4885 |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM4, TRPM6 | MGAM 3626/4885GAA 3828/4885SI 4140/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | MGAM 667/4885GAA 303/4885SI 34/4885 |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | MGAM 4078/4885GAA 3445/4885SI 3710/4885 |
| US-20180273517-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | MGAM 4078/4885GAA 3445/4885SI 3710/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | MGAM 667/4885GAA 303/4885SI 34/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | MGAM 667/4885GAA 303/4885SI 34/4885 |
| US-20090270355-A1 | Compounds | CMA1, HRH4, CCL11 | MGAM 2167/4885GAA 228/4885SI 447/4885 |
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | HRH1, HRH2, HRH4 | MGAM 4109/4885GAA 1039/4885SI 1721/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MGAM 3650/4885GAA 3334/4885SI 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.